A Role for RIP1 in Gliomagenesis

识别启动和抑制细胞凋亡的分子改变和信号传导异常， 维持胶质母细胞瘤（GBM）的恶性表型是设计 治疗NF-B和PI 3 K-Akt通路在GBM中被解除调节，并可能在GBM中发挥作用。 在GBM的发病机制和对治疗的抗性中起关键作用。NF-B活化是 炎症的标志在这个建议中，我们的目的是描述死亡的作用， 结构域包含激酶受体相互作用蛋白（RIP，RIP 1），在GBM生物学。 RIP 1激活神经胶质瘤细胞中的NF-B和PI 3 K-Akt通路。此外，RIP 1 负调节两个关键的肿瘤抑制信号网络，PTEN和 p53通路RIP 1水平在高达30%的GBM中升高，但在II-III级中不升高 神经胶质瘤此外，RIP 1表达导致GBM预后较差， 过表达RIP 1诱导胶质瘤细胞增殖，沉默RIP 1抑制胶质瘤细胞增殖。 在神经胶质瘤动物模型中神经胶质瘤细胞增殖。这个问题的核心假设是 RIP 1在GBM的发病机制中起着关键作用， 通过调节肿瘤细胞中的关键信号通路进行治疗。这个广泛的目标 一个建议是通过实验证明RIP 1促进恶性表型 的GBM。在具体目标1中，我们将探索RIP 1 神经胶质瘤细胞的增殖，并确定RIP 1特异性效应机制 影响胶质瘤细胞的增殖和对化疗的抗性。具体目标 2、探讨RIP 1介导的细胞凋亡的机制及生物学意义。 抑制肿瘤抑制信号传导。在具体目标3中，我们将对效果进行基准测试 RIP 1在神经胶质瘤细胞中的表达。这项研究可能 为炎症在GBM中的作用提供了有用的见解，并有助于设计 更有效的治疗靶向GBM中的炎症信号通路。

Identification of molecular alterations and signaling abnormalities that initiate and maintain the malignant phenotype in glioblastoma (GBM) is a key step in designing treatment. The NF-¿B and PI3K-Akt pathways are deregulated in GBM and likely to play key roles in the pathogenesis of GBM and in resistance to treatment. NF-¿B activation is a hallmark of inflammation. In this proposal, we aim to characterize the role of the death domain containing kinase receptor interacting protein (RIP, RIP1), in the biology of GBM. RIP1 activates both the NF-¿B and PI3K-Akt pathways in glioma cells. In addition, RIP1 negatively regulates two key tumor suppressor signaling networks, the PTEN and the p53 pathways. RIP1 levels are increased in up to 30% of GBMs but not in Grade II-III gliomas. Furthermore, RIP1 expression confers a worse prognosis in GBM, overexpressing RIP1 induces proliferation of glioma cells and silencing RIP1 inhibits proliferation of glioma cells in an animal model of glioma. The central hypothesis of this proposal is that RIP1 plays a key role in the pathogenesis of GBM and resistance to treatment by regulating key signaling pathways in tumor cells. The broad goal of this proposal is to demonstrate experimentally that RIP1 promotes the malignant phenotype of GBM. In Specific Aim 1, we will explore the mechanistic relationships coupling RIP1 to the proliferation of glioma cells and identify RIP1 specific effector mechanisms influencing proliferation and resistance to chemotherapy in glioma cells. In Specific Aim 2, we will determine the mechanisms and biological significance of RIP1 mediated inhibition of tumor suppressor signaling. In Specific Aim 3 we will benchmark the effect of RIP1 expression in glioma cells using an orthotopic animal model. This study may provide useful insights into the role of inflammation in GBM and help in the design of more effective treatments targeting inflammatory signaling pathways in GBM.